Kala Pharmaceuticals
Yahoo Finance • 16 days ago
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-... Full story
Yahoo Finance • last month
AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative
DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with... Full story
Yahoo Finance • last month
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s cont... Full story
Yahoo Finance • 4 months ago
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for th... Full story
Yahoo Finance • 4 months ago
KALA BIO to raise $10 mln in registered direct offering
* KALA BIO (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]) on Thursday said that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock, at $1.00 per share in a registered... Full story
Yahoo Finance • 4 months ago
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its commo... Full story
Yahoo Finance • 4 months ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 127,931,595 0.0325 0.0265 0.0315 -0.0025... Full story
Yahoo Finance • 8 months ago
KALA BIO Non-GAAP EPS of -$1.71
* KALA BIO press release [https://seekingalpha.com/pr/20194841-kala-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]): Q2 Non-GAAP EPS of -$1.71. * Cas... Full story
Yahoo Finance • 8 months ago
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to f... Full story
Yahoo Finance • 8 months ago
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe disease... Full story
Yahoo Finance • 9 months ago
Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder
Kala Bio, Inc. (NASDAQ:KALA), a small-cap biotech with a market capitalization of $33.29 million, announced Wednesday the completion of patient enrollment in its CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem ce... Full story
Yahoo Finance • 9 months ago
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass.,... Full story
Yahoo Finance • 11 months ago
KALA BIO to Present at Jefferies Global Healthcare Conference
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases... Full story
Yahoo Finance • last year
KALA BIO Announces Chief Executive Officer Transition
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe disease... Full story
Yahoo Finance • 2 years ago
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM... Full story
Yahoo Finance • 3 years ago
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2... Full story
Yahoo Finance • 3 years ago
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseas... Full story
Yahoo Finance • 3 years ago
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as inducement awards ou... Full story
Yahoo Finance • 3 years ago
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designatio... Full story
Yahoo Finance • 3 years ago
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t... Full story
